

**Question for written answer E-004975/2025
to the Commission**
Rule 144
Mathilde Androuët (PfE)

Subject: Preserving biomedical rigour in the face of ideological elements being introduced into European research

The study ‘Gender Inequalities in Medical Research, Drug Development and Access to Care’¹ points out the need to better take biological sex into account in medical research, in order to ensure timely diagnosis and appropriate treatment for the many women who are victims of delayed diagnosis and inadequate treatment.

However, the study systematically conflates biological sex and gender identity, seeks to integrate identity categories into medical protocols and considers gender identities as relevant clinical variables, in the same way as biological sex. The study presents that as a normative consensus, despite it being scientifically controversial.

Transgender issues are a key focus of the study, being referenced around 50 times. Such an emphasis could subject medicine to militant approaches and introduce into biomedicine ideological categories related to personal identity, which are not based on physiological realities.

Can the Commission confirm that:

1. biological sex will remain the baseline for EU-funded medical research?
2. the focus of European programmes will not be changed by social or identity transformation goals?
3. the priority will continue to be reducing health inequalities between women and men, rather than promoting ideological categories with no scientific basis?

Submitted: 17.12.2025

¹ *Gender Inequalities in Medical Research, Drug Development and Access to Care*, Policy Department for Citizens, Equality and Culture, Directorate-General for Citizens’ Rights, Justice and Institutional Affairs, European Parliament, PE 778.519, November 2025.